Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

The stock is down 3%, or $2.81, to $80.26 in premarket trading.Stay Ahead of the Market:Discover outperforming stocks and invest smarter with ...

Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed since the ...

President-elect Donald Trump has not backed down from insisting that the United States needs to acquire Greenland, a Danish ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

At the moment, the hottest GLP-1 treatment is Ozempic. Danish pharmaceutical leader Novo Nordisk (NYSE: NVO) is the brains behind Ozempic, as well as sibling GLP-1 medications including Wegovy ...

Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk NVO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...

Meanwhile, Novo Holdings’ $16.5 billion buyout of CDMO giant Catalent means that Novo Nordisk will soon secure three more fill-finish sites from its sister company.

Lars Fruergaard Jorgensen, Novo Nordisk’s boss ... not materialise—since the election Mr Trump has focused his ire on Mexico, Canada and China—but a more sceptical view of trade is certain ...